Now showing items 11-20 of 23
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study
Objectives Evidence is rapidly accumulating for the use of radical consolidative treatment (RCT) for patients with oligometastatic non-small cell lung cancer (NSCLC). Nonetheless, published studies have several limitations, ...
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
(International Institute of Anticancer Research, 2017)
Background: Heavily treated patients with nonsmall cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total ...
The reality of complexity: concomitant genomic alterations in patients with EGFR mutations
(AME Publishing, 2018)
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
(Blackwell Publishing Asia Pty, 2019)
Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: A phase 2 randomized clinical trial
(American Medical Association, 2019)
Importance Metformin hydrochloride is emerging as a repurposed anticancer drug. Preclinical and retrospective studies have shown that it improves outcomes across a wide variety of neoplasms, including lung cancer. ...
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)
Background A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies ...
Lung cancer disparities in hispanics: molecular diagnosis and use of immunotherapy
(American Society of Clinical Oncology, 2020-06-01)